Exploring New paradigms for Health

R&D

Dr Shaidah AsmallOctober 2007

Product Development

To global physical, mental and social well-being

Absence of Solutions

Validity of Assumptions • Pharma innovate drugs for developed countries

– Rate of Innovation decreasing Correa• Appropriate profit motive will lead to innovation

– IAVI one of first vaccine development initiatives– At present more than 80 in development– Big pharma actively involved in vaccine development– However limited success

• Lack of ability to pay– 20 years Chinese economy larger than USA – although % of poor will be large – today 700m below $2 day– Indian economy also expanding– Cover about a third of world population

Future Scenarios

• Biotech and Nanotech “revolution”– Rate of new developments in health are

increasing– However, majority at the conceptual stage– Known targets but looking for new

entities/delivery vehicles• Shorter Cycle “mind to market”

– IT cycle is about 15 months– Biotech cycle is about 30 months

Possible interventionsin value chain

• Prizes for ideas• Funding for development

– Patent pool;• CAMC for commercialisation

Acknowledgements